Employers Keep Cutting GLP-1 Coverage as Costs Outrun Plans
Covered enrollees fell from 3.6M in 2024 to 2.8M in 2026 as more employers and state plans drop GLP-1 obesity coverage. The retreat is now a clear trend, not a blip.
May 8, 2026 · 3 min read
The pullback in employer GLP-1 coverage that started as a 2025 story is now firmly a 2026 trend. Reporting tracking commercial coverage shows the number of US enrollees with GLP-1 obesity coverage falling from approximately 3.6 million in 2024 to 2.8 million in 2026 — a step-down driven by insurers, state employee plans, and small-business carriers all retreating from a benefit they say has become unaffordable.
What happened
Recent moves have been concentrated among regional Blue Cross plans and state-level programs. Blue Cross Blue Shield of Massachusetts has scaled back GLP-1 coverage for employers below a 100-employee threshold; Harvard Pilgrim Health Care, Blue Cross Blue Shield of Michigan, and North Carolina's Medicaid program have made similar policy adjustments over the past several months.
The driver is the same in every case: cost, mostly inclusive of expected utilization. Brand Wegovy and Zepbound list above $1,000 monthly before rebates, and uptake has consistently exceeded plan sponsors' modeling. UnitedHealthcare's leadership has said publicly that the additional GLP-1 spend has not been offset by reductions elsewhere in the medical-cost stack — a position several other payers have echoed in earnings calls.
For employees who do retain coverage, restrictions are tightening. Industry analyses indicate that around 88% of covered enrollees now face some form of barrier — most commonly prior authorization tied to BMI thresholds (often 35 or even 40), step therapy, or required participation in a lifestyle program before the drug is approved.
Why it matters
The economic logic that justified covering GLP-1s — that obesity-driven downstream costs would fall enough to offset drug spend — was always going to be a multi-year bet. Plans facing 2025 and 2026 renewal cycles haven't waited for that data. They've moved on price, with biosimilar timelines too far out to meaningfully relieve current-year budgets.
Patients land on the wrong side of this in three ways. The most direct: they lose access entirely and must either pay cash, switch to compounded versions (where regulation tightens), or stop the drug. The second: they retain access but face coverage that requires a new comorbidity diagnosis or a stricter BMI threshold than they meet. The third: they move plans during open enrollment specifically to keep coverage, often at higher premiums.
Our weight-regain after stopping cluster covers what's well-documented about discontinuation outcomes — relevant since coverage cuts force the question on people who didn't choose to stop.
What to watch
Three signals worth tracking through 2026. First, whether the federal Medicare GLP-1 Bridge program (launching July 1) shifts the broader political conversation enough to slow private retreats. Second, whether employers paying current pricing find ways to negotiate down — manufacturer-direct programs and pharmacy benefit manager contract renegotiations are both active right now. Third, the role of compounded GLP-1s as patients lose insurance: the FDA continues to tighten rules around 503A and 503B compounding even as demand from displaced patients climbs.
Sources
Sources